CMNP

Cet espace est réservé aux professionnels de santé.

Vous pourrez trouver ici différents documents scientifiques.

PUBLICATIONS MEDECINS DU CMNP

  • Berthet, L., Cochet, A., … & Brunotte, F. (2013). In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. Journal of Nuclear Medicine54(8), 1244-1250.
  • Bereau, M., Magnin, E., Nicolier, M., Berthet, L., … & Haffen, E. (2016). Left prefrontal repetitive transcranial magnetic stimulation in a logopenic variant of primary progressive aphasia: a case report. European Neurology76(1-2), 12-18.
  • Azizi, A., Blagosklonov, O., Lounis, A., Berthet, L., … & Delabrousse, E. (2015). Alveolar echinococcosis: correlation between hepatic MRI findings and FDG-PET/CT metabolic activity. Abdominal imaging40(1), 56-63.
  • Berthet, L. (2014). [18F]-FDG PET/CT Bests Gold Standard Bone Marrow Biopsy for Diagnosis and Prognosis of Lymphoma Patients. The Journal of OncoPathology. 1. 11-13.
  • Thibault, T., Durand-Bailloud, B., … & Samson, M. (2023). PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis. Rheumatology62(4), 1568-1575.
  • Houard, C., Pinaquy, J. B., … & Vendrely, V. (2017). Role of 18F-FDG PET/CT in posttreatment evaluation of anal carcinoma. Journal of Nuclear Medicine58(9), 1414-1420.
  • Humbert, O., Lasserre, M., Bertaut, A., Fumoleau, P., Coutant, C., Brunotte, F., & Cochet, A. (2018). Breast cancer blood flow and metabolism on dual-acquisition 18F-FDG PET: correlation with tumor phenotype and neoadjuvant chemotherapy response. Journal of Nuclear Medicine59(7), 1035-1041.
  • Foret, T., Dhomps, A., … & Tordo, J. (2019). FDG PET/CT of Gardnerella vaginalis infection. Clinical Nuclear Medicine44(8), 660-662.
  • Dhomps, A., Foret, T., … & Tordo, J. (2019). Isolated muscular sarcoidosis revealed by hypercalcemia and 18F-FDG PET/CT. Clinical Nuclear Medicine44(10), 824-825.
  • Dudoignon, B., Tainturier, L. E., … & Arnulf, I. (2021). Functional brain imaging using 18F-fluorodeoxyglucose positron emission tomography/computerized tomography in 138 patients with Kleine–Levin syndrome: an early marker?. Brain Communications3(2), fcab130
  • Aide, N., Tainturier, L. E., … & Lasnon, C. (2020). HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological 18F-FDG anal uptake. EJNMMI research10(1), 28.
  • Grambow-Velilla, J., Mahida, B., … & Hyafil, F. (2023). Prognosis and follow-up of patients with prosthetic valve endocarditis treated conservatively in relation to WBC-SPECT imaging. Journal of Nuclear Cardiology30(6), 2633-2643.
  • Kooshki, N., Grambow-Velilla, J., … & Hyafil, F. (2022). Diagnostic performance of White Blood Cell SPECT imaging against intra-operative findings in patients with a suspicion of prosthetic valve endocarditis. Journal of Nuclear Cardiology29(2), 528-534.
  • Grambow-Velilla, J., Seban, R. D., … & Duchemann, B. (2023). Total metabolic tumor volume on 18F-FDG PET/CT is a useful prognostic biomarker for patients with extensive small-cell lung cancer undergoing first-line chemo-immunotherapy. Cancers15(8), 2223.
  • Lépinoy, A., Silva, Y. E., Martin, E., Bertaut, A., Quivrin, M., Aubignac, L., … & Créhange, G. (2019). Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging46(1), 40-48.
  • Silva, Y., Riedinger, J. M., Chrétien, M. L., Caillot, D., Corre, J., Guillen, K., … & Loffroy, R. (2021). Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients. Quantitative Imaging in Medicine and Surgery11(10), 4299.

ETUDES EN COURS OU AYANT EU LIEU AU CMNP

Etude STEREO-OS: étude évaluant une radiothérapie stéréotaxique extra-crânienne associée au traitement standard par rapport à un traitement standard seul, chez les patients atteints d’une tumeur solide avec moins de 3 métastases osseuses sans atteinte viscérale : 

 

Etude ARASTEP : étude de phase 3 randomisée, visant à évaluer l’efficacité et l’innocuité du traitement par darolutamide associé à un traitement de privation androgénique (TPA) par rapport à un placebo associé à un traitement par un TPA, chez des patients présentant un risque élevé de récidive biochimique du cancer de la prostate.